Abstract
A new macrolide antibiotic preparation, TMS-19-Q•O tablet, was used to investigate the efficacy in the treatment of patients with respiratory tract infection, and the results obtained were as follows: 1. Three handred and seven cases were included in this report, and overall efficacy rate was 16.1%, Especially high clinical effect (86.0%) was observed in the treatment of patients with pneumonia including mycoplasmal pneumonia. 2. Bacteriological effect was 87.5% in 51 cases identified as single infection of Gram-positive cocci and was 48.0% in 34 cases Gram-negative rods infection. 3. Side effects were observed in 11 cases (3.50%): gastrointestinal disorder in 8, eruption in 2 and other in 1. Abnormality in laboratory tests was observed in 23 cases, hepatic disorder in 13, renal disorder in 3 and other laboratory tests in 7. 4. It was considered from the results of clinical and bacteriological efficacy in different dose study that dose of TMS-19-Q should be 600 mg.
Original language | English |
---|---|
Pages (from-to) | 553-574 |
Number of pages | 22 |
Journal | The Japanese Journal of Antibiotics |
Volume | 38 |
Issue number | 3 |
DOIs | |
Publication status | Published - 1985 |
Externally published | Yes |
ASJC Scopus subject areas
- Microbiology (medical)
- Pharmacology (medical)
- Infectious Diseases